secwatch.observer — SEC 8-K summary
======================================

Issuer:     GILEAD SCIENCES, INC. (GILD)
CIK:        0000882095
Form:       8-K
Filed at:   2026-08-04T20:03:26+00:00
Accession:  0000882095-26-000028
Event type: earnings
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead Q2 2026 Revenue Up 10% to $7.8B; Diluted Loss Per Share $(8.45) on $11.2B IPR&D Charges
--------------------------------------------------------------------------------

- Total Q2 2026 revenues increased 10% to $7.8 billion compared to Q2 2025.
- Product sales excluding Veklury increased 10% to $7.6 billion, driven by HIV portfolio, Trodelvy, and Livdelzi.
- Diluted loss per share was $(8.45) due to $11.2 billion in acquired IPR&D expenses from Arcellx, Tubulis, and Ouro Medicines acquisitions.
- Biktarvy sales increased 7% to $3.8 billion; Descovy sales up 48% to $967 million.
- Gilead updated 2026 guidance: product sales ex-Veklury now $29.8B-$30.1B, up from prior $29.4B-$29.8B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882095/000088209526000028/0000882095-26-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882095/000088209526000028/gild-20260804.htm
  HTML page:      https://secwatch.observer/filing/0000882095-26-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer